BioSpace News Archive

AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company, specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, announced today that a single-arm open label design with a randomized withdrawal phase for its ongoing pivotal Phase 3 trial under an Investigational New Drug (IND) Application for its product candidate Tadekinig alfa, has been accepted by the U.S. Food and Drug Administration (FDA).

Rite Aid Corporation (NYSE: RAD) announced that its stockholders approved a reverse stock split of the company’s common stock at today’s Special Meeting of Stockholders. According to preliminary tabulations, with approximately 987 million eligible votes cast, stockholders voted 78% in favor of the reverse split.

New medical innovation campus to be home to most advanced cancer care in D.C. region

So long to the days of drinking sugar bombs and face-puckering beverages to help aid digestion.

Sapio Sciences is pleased to announce the availability of Exemplar LIMS/ELN 11, a major expansion of our leading informatics platforms capabilities

Multiple Sclerosis Association of America focuses 2019 awareness campaign on family, relationships and care partner needs

Agreement Empowers Caribbean Community to Use Location Intelligence for Data-Driven Policy Initiatives

Healthcare Technology and Facilities Management Webinars Approved for up to 11 CEUs Toward AAMI Certification

Georgia Urology, the largest urology practice in Atlanta and throughout the Southeast, today announced that they will be surpassing the treatment of more than 350 patients with the UroLift® System, a proven, minimally invasive technology to treat men suffering from symptoms associated with Benign Prostatic Hyperplasia, or BPH.

GestVision, Inc., a privately-held biotechnology company, applauds the diligent work of the clinical researchers who conducted the first prospective clinical study of a rapid CRD urine diagnostic for confirming or ruling out preeclampsia